Document is current

Article History

Received: 23 July 2025

Accepted: 18 October 2025

First Online: 29 November 2025

Declarations

:

: All study materials were submitted to the Western Copernicus Group institutional review board (WCGIRB) for ethical review. The initial study materials were approved on June 27, 2024, and further minor amendments to study materials and consent forms were approved on November 21, 2024 [IRB tracking number: 20242521].

: All participants provided informed consent for their data to be used anonymously or in aggregate prior to entering the study.

: PY: Consulting/honoraria/support for attending meetings: BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharming, Pharvaris, and Takeda. TJC: Speaker/researcher: Astria, CSL Behring, KalVista Pharmaceuticals, and Takeda; researcher: ADARx, BioMarin, Intellia, Ionis, and Pharvaris; speaker: Grifols; consultant: ADARx, Astria, BioCryst, CSL Behring, Intellia, KalVista Pharmaceuticals, Pharvaris, and Takeda; Director of the ACARE International Hereditary Angioedema Center; member of the Medical Advisory Board for the United States Hereditary Angioedema Association (HAEA). PB: Consulting: ADARx, Astria, Behring, BioCryst, CSL, CVS Specialty, KalVista Pharmaceuticals, Pharvaris, and Takeda. TG: Consulting/advisory work/educational support: BioCryst, CSL Behring, KalVista Pharmaceuticals, Novartis, Octapharma, Pharming, Pharvaris, and Takeda. CD, RH, and SHL: Employees: Acaster Lloyd Consulting. Acaster Lloyd Consulting was commissioned by KalVista Pharmaceuticals to conduct the study. PA and AW: Employees: KalVista Pharmaceuticals. AB: Research grants: BioCryst and Takeda; consulting: BioCryst, BioMarin, CSL, KalVista Pharmaceuticals, Pharming, Pharvaris, and Takeda. SK-A: Speaker/consultancy: BioCryst, CSL Behring, Pharming, and Takeda.